EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 336 filers reported holding EXELIXIS INC in Q4 2019. The put-call ratio across all filers is 0.79 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $36,055,137 | -13.5% | 1,604,590 | -8.6% | 0.08% | -17.5% |
Q1 2024 | $41,667,270 | -5.6% | 1,755,890 | -4.6% | 0.10% | -5.8% |
Q4 2023 | $44,153,355 | -8.7% | 1,840,490 | -16.9% | 0.10% | -16.9% |
Q3 2023 | $48,380,052 | +10.2% | 2,214,190 | -3.6% | 0.12% | +10.7% |
Q2 2023 | $43,914,589 | +35.4% | 2,297,990 | +37.5% | 0.11% | +33.3% |
Q1 2023 | $32,441,680 | +82.0% | 1,671,390 | +50.4% | 0.08% | +68.0% |
Q4 2022 | $17,821,884 | +2.5% | 1,111,090 | +0.2% | 0.05% | 0.0% |
Q3 2022 | $17,380,000 | -54.3% | 1,108,390 | -39.3% | 0.05% | -53.7% |
Q2 2022 | $37,994,000 | -18.0% | 1,824,890 | -10.7% | 0.11% | -12.2% |
Q1 2022 | $46,337,000 | +10.3% | 2,043,990 | -11.0% | 0.12% | +17.1% |
Q4 2021 | $42,000,000 | -10.4% | 2,297,590 | +3.7% | 0.10% | -13.2% |
Q3 2021 | $46,857,000 | +103.5% | 2,216,490 | +75.4% | 0.12% | +98.4% |
Q2 2021 | $23,023,000 | +60.7% | 1,263,590 | +99.2% | 0.06% | +56.4% |
Q1 2021 | $14,326,000 | +48.4% | 634,190 | +31.9% | 0.04% | +50.0% |
Q4 2020 | $9,653,000 | -17.7% | 480,990 | +0.3% | 0.03% | -23.5% |
Q3 2020 | $11,728,000 | -50.0% | 479,690 | -51.4% | 0.03% | -50.7% |
Q2 2020 | $23,436,000 | +1269.7% | 987,190 | +893.8% | 0.07% | +885.7% |
Q1 2020 | $1,711,000 | -65.8% | 99,335 | -65.0% | 0.01% | -41.7% |
Q4 2019 | $4,998,000 | -58.1% | 283,635 | -58.0% | 0.01% | -58.6% |
Q3 2019 | $11,934,000 | +14.5% | 674,835 | +38.4% | 0.03% | +11.5% |
Q2 2019 | $10,419,000 | +4449.8% | 487,535 | +4091.7% | 0.03% | +2500.0% |
Q4 2018 | $229,000 | -99.0% | 11,631 | -98.9% | 0.00% | -98.4% |
Q2 2018 | $23,270,000 | -38.4% | 1,081,321 | -36.6% | 0.06% | -38.2% |
Q1 2018 | $37,782,000 | -65.3% | 1,705,721 | -52.4% | 0.10% | -65.3% |
Q4 2017 | $108,909,000 | +8.3% | 3,582,521 | -13.7% | 0.29% | +3.2% |
Q3 2017 | $100,538,000 | -1.9% | 4,149,338 | -0.3% | 0.28% | -15.7% |
Q2 2017 | $102,521,000 | +4.9% | 4,162,464 | -7.7% | 0.34% | +5.6% |
Q1 2017 | $97,715,000 | +91.1% | 4,509,221 | +31.5% | 0.32% | +63.3% |
Q4 2016 | $51,125,000 | +122.6% | 3,428,900 | +90.9% | 0.20% | +100.0% |
Q3 2016 | $22,972,000 | +200.5% | 1,796,103 | +83.5% | 0.10% | +151.3% |
Q2 2016 | $7,644,000 | +169.7% | 978,790 | +38.2% | 0.04% | +143.8% |
Q1 2016 | $2,834,000 | +91.6% | 708,390 | +170.2% | 0.02% | +77.8% |
Q4 2015 | $1,479,000 | +30.7% | 262,190 | +30.1% | 0.01% | +28.6% |
Q3 2015 | $1,132,000 | +3134.3% | 201,496 | +729.5% | 0.01% | – |
Q4 2014 | $35,000 | – | 24,290 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
Signition LP | 84,120 | $1,798,000,000 | 1.18% |
Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |